Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.

J Adv Pract Oncol · 2014 · PMC4457180 · PMID 26110069

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

The interim analysis of OS data showed a strong trend toward a survival benefit with pertuzumab/trastuzumab/docetaxel therapy, although it did not reach significance ( Baselga & Swain, 2010 ).

also in 5,725 other papers

showed a trendno p-value reported

The interim analysis of OS showed a trend in favor of ado- trastuzumab emtansine, but it did not reach a level of statistically significant benefit ( Wildiers et al., 2013 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.